L04AA08 • daclizumab • Antineoplastic and immunomodulating agents | Immunosuppressants | Selective immunosuppressants
Daclizumabum is an immunomodulatory medication previously used for the treatment of relapsing multiple sclerosis. It worked by blocking the interleukin-2 (IL-2) receptor, reducing immune system activity that attacks the myelin in the central nervous system.
The medication was administered as subcutaneous injections, usually once a month. While effective in reducing relapse frequency, its use was associated with significant risks.
Side effects included infections, injection site reactions, fatigue, and, in rare cases, severe liver conditions or autoimmune disorders. Due to these risks, Daclizumabum was withdrawn from the market in many countries.
Consult your doctor for safe and effective alternatives for managing multiple sclerosis. Close monitoring is essential to manage this condition effectively.
Substance: daclizumab
Date of last drug list: 01-07-2013
Commercial code: W07557002
Concentration: 5mg / ml
Pharmaceutical form: concentrate for solution for infusion
Quantity: 3
Product type: original
Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.